The annual Rotorua GP CME conference and medical exhibition took place from 10-13 June, 2021. Associate Professor Gerry Devlin spoke at a breakfast symposium sponsored by Novartis where he provided an overview of the epidemiology and prognosis of heart failure in New Zealand, as well as information about evolving medical therapies and trouble shooting tips for primary care. He also reviewed the evidence supporting the use of sacubitril/valsartan (Entresto®) in the treatment of patients with heart failure with reduced ejection fraction. This review summarises the key points from Associate Professor Devlin’s presentation.
Please login below to download this issue (PDF)